Regeneron Pharmaceuticals (REGN) stock
REGN · Regeneron Pharmaceuticals Inc. · NASDAQ
What is the latest news on REGN stock?
REGN fell 0.26% to $921.22 on Nov 20, 2026. No REGN story in the last two days; the most recent is below.
S-8 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
All REGN newsWho owns the most REGN stock?
BlackRock, Inc. was the largest reported holder of REGN at the end of Q2 2026, with 9,113,506 shares worth $5.7 billion. Next came Vanguard Capital Management LLC ($4.1 billion) and Dodge & Cox ($3.0 billion). In all, 1,332 institutions reported $57.2 billion of REGN in their 13F filings.
All REGN fund holdersAre insiders buying or selling REGN?
Insiders are selling. In the last 90 days 9 insiders sold $56.0 million of REGN in trades reported on Form 4. The latest: George L Sing sold $1.9 million, reported on Nov 18, 2026.
REGN insider tradesFinancial highlights
Full financials- Revenue, TTM
- $16.90B
- Revenue growth
- +18.6%
- Net income, TTM
- $4.82B
- Net margin
- 28.5%
- Free cash flow, TTM
- $3.83B
- Cash
- $3.66B
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
Latest news
25 items- SECSEC Form S-8 filed by Regeneron Pharmaceuticals Inc.S-8 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
- FDAFDA Approval for LIVSAYIS issued to REGENERON PHARMACEUTICALSSubmission status for REGENERON PHARMACEUTICALS's drug LIVSAYIS (ORIG-1) with active ingredient CEMDISIRAN has changed to 'Approval' on 11/18/2026. Application Category: NDA, Application Number: 221251, Application Classification: Type 1 - New Molecular Entity
- PRRegeneron Highlights New Data Across Malignant and Classical Hematology Programs at American Society of Hematology (ASH)Primary analysis from a potentially pivotal trial of Ordspono® (odronextamab) in patients with R/R marginal zone lymphoma (MZL) to be shared in an oral presentation, part of a clinical development program evaluating Ordspono across a broad spectrum of lymphoma settings New data on Lynozyfic® (linvoseltamab) in R/R systemic light chain (AL) amyloidosis also to be shared in an oral presentation, also part of a clinical development program evaluating Lynzoyfic across a broad spectrum of multiple myeloma settings and precursor conditions Additional presentations across a broad range of programs highlight next wave of innovation in blood disorders TARRYTOWN, N.Y., Nov. 19, 2026 (GLOBE NEWSWI
- PRLivsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous DosingApproval based on Phase 3 NIMBLE results demonstrating rapid, deep and sustained disease control that is maintained throughout three-month dosing intervals Livsayis is Regeneron's first approved siRNA therapy and neurology medicine TARRYTOWN, N.Y., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Livsayis™ (cemdisiran) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive, the predominant form of the disease. Livsayis is a novel, complement component factor 5 (C5)-directed small interfering RNA (siR
- INSIDERDirector George L Sing sold $1,917,945 worth of shares (2,000 units at $958.97), decreasing direct ownership by 8% to 23,147 units (SEC Form 4)4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
- INSIDEREVP Commercial Marion Mccourt sold $543,504 worth of shares (566 units at $960.25) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 10,305 units (SEC Form 4)4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
- INSIDERCo-Chief Scientific Officer Andrew J Murphy exercised 17,000 shares at a strike of $381.92, covered exercise/tax liability with 11,989 shares and sold $4,799,336 worth of shares (5,011 units at $957.76) as part of a pre-agreed trading plan (SEC Form 4)4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
- PRLibtayo® (cemiplimab) Approved in the European Union (EU) for Extended Dosing and Faster Infusion Times Across Skin, Lung and Cervical Cancer IndicationsApproval introduces an extended dosing regimen of Libtayo 700 mg given every six weeks, following initial 12 weeks of treatment with Libtayo 350 mg every three weeks Also approved is an option of reducing subsequent infusion times of Libtayo 350 mg by up to half, from 30 minutes to 15 minutes, after a well-tolerated 30-minute infusion TARRYTOWN, N.Y., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that the European Commission (EC) has approved an alternative, flexible dosing schedule for Libtayo® (cemiplimab) across all approved skin, lung and cervical cancer indications. The EC approval provides patients with the option to receive a highe
- PRPOTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic SymptomsData presented today for the first time at the American Autonomic Society (AAS) annual meeting POTS (postural orthostatic tachycardia syndrome) is a debilitating condition characterized by a marked increase in heart rate upon standing and associated orthostatic symptoms, with no FDA-approved treatments available A single dose of baloncibart reduced the exaggerated heart rate response to standing and improved orthostatic symptoms through four weeks; biomarker changes were consistent with plasma volume expansion, the intended effect of NPR1 blockade Potentially pivotal Phase 3 trial planned for first half of 2027 TARRYTOWN, N.Y., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceutica
- PRCIDEB siRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLDSingle administration of CIDEBsiRNA resulted in rapid, deep and durable reductions in liver fat by up to 80% that were sustained through 36 weeks Data from first-in-human trial were shared in oral presentation at AASLD The Liver Meeting® and simultaneously published in The New England Journal of Medicine Regeneron to host virtual "Regeneron Roundtable" investor event to discuss its MASH pipeline programs on Tuesday, November 10 at 8:30 a.m. ET TARRYTOWN, N.Y., Nov. 08, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the first results from a first-in-human trial that demonstrated a single subcutaneous dose of CIDEBsiRNA rapidly normalized liver fat
- INSIDERSVP Controller Pitofsky Jason exercised 3,883 shares at a strike of $640.66 and sold $3,827,159 worth of shares (4,062 units at $942.19) (SEC Form 4)4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
- INSIDERCo-Chief Scientific Officer Murphy Andrew J gifted 1,054 shares, decreasing direct ownership by 2% to 46,779 units (SEC Form 4)4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
- SECSEC Form 13F-HR filed by Regeneron Pharmaceuticals Inc.13F-HR - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
- INSIDERDirector Zoghbi Huda Y exercised 7,439 shares at a strike of $380.95 and sold $7,219,274 worth of shares (7,439 units at $970.46) (SEC Form 4)4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
- INSIDERDirector Sing George L exercised 15,269 shares at a strike of $378.77 and sold $20,376,358 worth of shares (21,129 units at $964.38), decreasing direct ownership by 19% to 25,147 units (SEC Form 4)4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
- INSIDERDirector Poon Christine A exercised 7,830 shares at a strike of $376.69 and sold $7,587,958 worth of shares (7,830 units at $969.09) (SEC Form 4)4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
- INSIDEREVP Finance CFO Fenimore Christopher R. exercised 6,000 shares at a strike of $381.92, covered exercise/tax liability with 4,243 shares and gifted 15 shares, increasing direct ownership by 9% to 21,726 units (SEC Form 4)4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
- INSIDEREVP General Counsel and Secret Larosa Joseph J exercised 12,283 shares at a strike of $381.92, covered exercise/tax liability with 8,686 shares and sold $4,311,890 worth of shares (4,466 units at $965.49), decreasing direct ownership by 2% to 38,906 units (SEC Form 4)4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
- INSIDERDirector Guarini Kathryn exercised 400 shares at a strike of $719.37 and sold $360,000 worth of shares (400 units at $900.00) as part of a pre-agreed trading plan (SEC Form 4)4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
- INSIDERDirector Brown Michael S exercised 1,929 shares at a strike of $725.89 and sold $1,687,875 worth of shares (1,929 units at $875.00) as part of a pre-agreed trading plan (SEC Form 4)4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
- INSIDEREVP Commercial Mccourt Marion sold $984,195 worth of shares (1,132 units at $869.43) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 10,871 units (SEC Form 4)4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
- PRRegeneron Announces Investor Conference PresentationsTARRYTOWN, N.Y., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: 2026 Jefferies Global Healthcare Conference in London at 2:00 p.m. GMT (9:00 a.m. ET) on Tuesday, November 17, 20269th Annual Evercore Healthcare Conference at 1:45 p.m. ET on Tuesday, December 1, 2026Citi’s 2026 Global Healthcare Conference at 9:40 a.m. ET on Wednesday, December 2, 2026 The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcasts will be archived on the Company's website for at least 30 days. About Re
- SECSEC Form 10-Q filed by Regeneron Pharmaceuticals Inc.10-Q - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
- SECRegeneron Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
- PRRegeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. PreparednessUpdated agreement expands 2020 procurement agreement with BARDA for Regeneron's first-in-class antibody treatment for Orthoebolavirus zairense, adding value of approximately $270 million TARRYTOWN, N.Y., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced today that it has extended its agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to provide additional supply of Inmazeb® (a three-antibody cocktail of atoltivimab, maftivimab, and odesivimab-ebgn) for U.S. preparedness against Ebola
REGN rankings
- Insider16(39%)
- Other15(37%)
- SEC Filings5(12%)
- Earnings4(10%)
- Analyst1(2%)
Our reporting on REGN
- FDA approves Regeneron's Livsayis, the first siRNA drug for myasthenia gravis, dosed every three monthsAnalysis · Nov 19, 2026 · 6 min read

- J&J agrees to buy eye-disease biotech Ollin, a $3.4 billion entry into retina drugsAnalysis · Nov 16, 2026 · 7 min read

- AbbVie Submits FDA Application for Etentamig in Relapsed Multiple Myeloma After Phase 3 Trial Shows 60% Risk ReductionAnalysis · Oct 27, 2026 · 3 min read

Regeneron Pharmaceuticals Inc. (REGN) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 26 wire items for REGN, including 13 insider trades, 9 press releases and news items and 3 SEC filings. The most recent was published Nov 19, 2026.
REGN FAQ
11 questionsWhat does Regeneron Pharmaceuticals Inc. do?
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults...What is REGN revenue?
Regeneron Pharmaceuticals Inc. (REGN) reported $16.90B of revenue for the twelve months ended Sep 30, 2026. That is up 18.6% from the year before. Revenue for fiscal 2025 was $14.34B.Is REGN profitable?
Yes. Regeneron Pharmaceuticals Inc. earned $4.82B in net income for the twelve months ended Sep 30, 2026, a net margin of 28.5%.How much cash and debt does REGN have?
Regeneron Pharmaceuticals Inc. reported $3.66B in cash and cash equivalents and $1.99B of debt on its most recent balance sheet in SEC filings.Where does REGN stock trade?
Regeneron Pharmaceuticals Inc. (REGN) is listed on NASDAQ.What sector and industry is REGN in?
Regeneron Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Regeneron Pharmaceuticals Inc. go public?
Regeneron Pharmaceuticals Inc. (REGN) completed its IPO in 1991.Does REGN pay a dividend?
REGN's most recent ex-dividend date was 2026-11-20 with a cash dividend of $0.94 per share. No future ex-date is on file yet.What are analysts saying about REGN?
Across the last 8 analyst actions on Regeneron Pharmaceuticals Inc., there were 2 upgrades and 3 downgrades. The most recent action was from Argus: Buy with a $850.00 price target on 2026-10-01. Recent price targets range from $641.00 to $923.00.What companies are similar to REGN?
Notable peers in the same industry include JNJ (Johnson & Johnson), MRK (Merck & Company Inc.), GILD (Gilead Sciences Inc.), AMGN (Amgen Inc.), VRTX (Vertex Pharmaceuticals Incorporated). Compare REGN side-by-side with any of them on Quantisnow.How can I track REGN on Quantisnow?
Quantisnow aggregates Regeneron Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow REGN to receive live email and push alerts on every new disclosure.
Is something on this page wrong, or out of date? Request a change